Key clinical point: Radiofrequency ablation was associated with improved survival in HCC patients with early and intermediate stage HCC.
Major finding: The survival in patients with liver cancer due to HCC was 82.3% at 12 months and 57.8% at 36 months for patients who received radiofrequency ablation.
Study details: The data come from a retrospective cohort study of 62 adults with HCC; of these, 32.3% were early stage, based on Barcelona-Clinic Liver Cancer staging system (BCLC) A, and 67.7% were intermediate, based on BCLC B. A total of 46 patients underwent radiofrequency ablation as their first-line treatment.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Sulaiman AS et al. J Gastrointest Cancer. 2021 Aug 11. doi: 10.1007/s12029-021-00676-0.